As a valued subscriber to the wealth of resources published by Relias Media, we are sending this reminder that your new issue is now available online. The articles in this issue are listed below:
In a randomized clinical trial, researchers found the combination of oral vancomycin followed by fecal microbiota transplantation was superior to treatment with fidaxomicin or vancomycin alone for patients with recurrent Clostridioides difficile infection.
Coinfection with methicillin-resistant Staphylococcus aureus (MRSA) in children with influenza is associated with high fatality. Data support the addition of a second anti-MRSA antibiotic to vancomycin in severely ill children.
Histoplasmosis is increasingly seen beyond the previous risk areas of the Ohio and Mississippi River valleys. Diagnostic and treatment practices vary widely.
Omadacycline was approved in 2018 by the U.S. Food and Drug Administration (FDA) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).
Financial Disclosure: Peer Reviewer Patrick Joseph, MD, is a consultant for Genomic Health Reference Laboratory, Siemens Clinical Laboratory, and CareDx Clinical Laboratory. Infectious Disease Alert’s Editor Stan Deresinski, MD, FACP, FIDSA, Updates Author Carol A. Kemper, MD, FACP, Peer Reviewer Kiran Gajurel, MD, Executive Editor Shelly Morrow Mark, Editor Jonathan Springston, and Editorial Group Manager Leslie Coplin report no financial relationships to this field of study.
